Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Gene | CBL |
Variant | dec exp |
Impact List | none |
Protein Effect | no effect |
Gene Variant Descriptions | CBL dec exp indicates decreased expression of the Cbl protein. However, the mechanism causing the decreased expression is unspecified. |
Associated Drug Resistance | |
Category Variants Paths |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
CBL dec exp | pancreatic ductal carcinoma | predicted - sensitive | Erlotinib + Gemcitabine | Preclinical - Cell line xenograft | Emerging | In a preclinical study, addition of Tarceva (erlotinib) overcame Gemzar (gemcitabine)-resistance in pancreatic ductal carcinoma cell lines with reduced Cbl expression via shRNA, resulted in decreased viability in cell culture and reduced tumor growth in cell line xenograft models (PMID: 25348515). | 25348515 |